Novo Nordisk ADR (NYSE:NVO) currently has a daily average trading volume of 8.59M but it saw 13174639 shares traded in last market. With a market cap of 218.97B USD, the company’s current market price of $65.09 came rising about 5.67 while comparing to the previous closing price of $61.60. In past 52 weeks, the stock remained buoying in the range of price level as high as $148.15 and as low as $60.61. In the recent trading on the day, stock has struck highest price mark of $59.515 while lowest mark touched by it was $65.3.
Taking a look at 20-day trading activity of Novo Nordisk ADR (NVO) gives us an average price of $71.73, while its current price level is -56.06% below from 52-week high level whereas it is 7.40% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $79.65 while that of 200 days or SMA-200 reads an average of $107.94. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.33% during that period while stretching the period over a month that decreases to 3.31%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 33.56 which implies that the stock is in neutral territory.
Over the week, NVO’s stock price is moving -4.62% down while it is -16.67% when we observe its performance for the past one month. Year-to-date it is -24.33% down and over the past year, the stock is showing a downside performance of -48.93%.
The company is expected to be releasing its next quarterly report on 2025-Feb-04, for which analysts forecasted an EPS of 6.09 while estimate for next year EPS is 26.71. In next quarter, company is expected to be making quarterly sales of $81.87B as analysts are expecting the sales for current fiscal year at $350.34B and seeing the company making $408.82B in sales next year. Moreover, analysts are in estimates of $79.17B for current-quarter revenue.
Currently, Novo Nordisk ADR’s total number of outstanding shares is 3.37B with 0.00% of that held by the insiders while 10.27% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 45.25% and return on equity (ROE) at 82.03%. It has a price to earnings ratio (P/E ratio) of 19.83 while having a 13.60 of forward P/E ratio. Stock’s beta reads 0.69. Stock has a price to book (P/B) ratio of 14.51 while price to sale or P/S ratio amounts to 5.20. Its return on asset (ROA) is 26.33% on average.
